Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498167 | 0.90 | DYRK1A (0.36) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL17624370 | 0.82 | LMNA (0.39) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL19498168 | 0.81 | MAPT (0.41) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL19498563 | 0.81 | MAPT (0.34) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL19498171 | 0.79 | TSHR (0.37) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL19504882 | 0.79 | MAPT (0.38) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL19498179 | 0.78 | HSP90AB1 (0.47) | MAPTLMNAPOLBHSP90AB1 | |
| SCHEMBL19498172 | 0.76 | MAPT (0.35) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL13322763 | 0.72 | HSP90AA1 (0.40) | HSP90AB1PDE10A | |
| SCHEMBL13562736 | 0.72 | DPP4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | MAPT 2148/4885LMNA 2796/4885TP53 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.